Enliven Therapeutics (ELVN) Common Equity (2019 - 2026)

Enliven Therapeutics has disclosed Common Equity across 8 years of filings, most recently posting $453.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $453.4 million, up 57.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $453.4 million (up 57.26% YoY), and the FY2025 annual result was $459.6 million, up 48.33% from the prior year.
• Common Equity came in at $453.4 million for Q1 2026 at Enliven Therapeutics, down from $459.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $488.5 million in Q2 2025 to a low of -$76.8 million in Q4 2022.
• The 5-year median for Common Equity is $288.4 million (2024), against an average of $247.7 million.
• Across the five-year window, Common Equity slumped 190.37% in 2022 and soared 675.81% in 2023, its largest moves.
• Enliven Therapeutics' Common Equity stood at -$76.8 million in 2022, then soared by 420.09% to $245.9 million in 2023, then advanced by 26.0% to $309.8 million in 2024, then jumped by 48.33% to $459.6 million in 2025, then decreased by 1.36% to $453.4 million in 2026.
• The last three Common Equity figures came in at $453.4 million (Q1 2026), $459.6 million (Q4 2025), and $476.1 million (Q3 2025), per Business Quant data.